Balyasny Asset Management LLC bought a new stake in Cardiovascular Systems, Inc. (NASDAQ:CSII) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 13,221 shares of the medical device company’s stock, valued at approximately $426,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. grew its position in shares of Cardiovascular Systems by 12.6% in the 2nd quarter. Vanguard Group Inc. now owns 1,864,604 shares of the medical device company’s stock valued at $60,096,000 after buying an additional 208,248 shares during the last quarter. State Street Corp grew its position in shares of Cardiovascular Systems by 14.2% in the 1st quarter. State Street Corp now owns 671,388 shares of the medical device company’s stock valued at $18,982,000 after buying an additional 83,602 shares during the last quarter. New York State Common Retirement Fund grew its position in shares of Cardiovascular Systems by 346.8% in the 2nd quarter. New York State Common Retirement Fund now owns 443,304 shares of the medical device company’s stock valued at $14,288,000 after buying an additional 344,082 shares during the last quarter. Northern Trust Corp grew its position in shares of Cardiovascular Systems by 4.9% in the 2nd quarter. Northern Trust Corp now owns 441,314 shares of the medical device company’s stock valued at $14,224,000 after buying an additional 20,434 shares during the last quarter. Finally, Marshall Wace North America L.P. grew its position in shares of Cardiovascular Systems by 23.8% in the 2nd quarter. Marshall Wace North America L.P. now owns 382,924 shares of the medical device company’s stock valued at $12,254,000 after buying an additional 73,513 shares during the last quarter. 74.50% of the stock is currently owned by hedge funds and other institutional investors.

Cardiovascular Systems, Inc. (NASDAQ CSII) opened at 26.59 on Thursday. The firm’s 50-day moving average is $28.80 and its 200 day moving average is $30.24. Cardiovascular Systems, Inc. has a 12 month low of $21.29 and a 12 month high of $33.11. The stock’s market capitalization is $877.23 million.

Cardiovascular Systems (NASDAQ:CSII) last released its earnings results on Wednesday, August 2nd. The medical device company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.07. Cardiovascular Systems had a negative net margin of 0.87% and a positive return on equity of 0.88%. The firm had revenue of $52.90 million during the quarter, compared to analyst estimates of $51.98 million. During the same quarter in the previous year, the firm earned ($0.15) earnings per share. The firm’s revenue for the quarter was up 9.1% compared to the same quarter last year. On average, equities analysts anticipate that Cardiovascular Systems, Inc. will post $0.01 earnings per share for the current year.

WARNING: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/10/19/balyasny-asset-management-llc-buys-shares-of-13221-cardiovascular-systems-inc-csii.html.

In other Cardiovascular Systems news, Director Edward M. Brown sold 13,031 shares of the business’s stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $29.09, for a total transaction of $379,071.79. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Scott R. Ward sold 5,529 shares of the business’s stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $30.41, for a total transaction of $168,136.89. Following the sale, the chief executive officer now owns 282,536 shares of the company’s stock, valued at approximately $8,591,919.76. The disclosure for this sale can be found here. In the last quarter, insiders have sold 51,065 shares of company stock valued at $1,514,031. 3.30% of the stock is owned by insiders.

A number of research analysts recently commented on CSII shares. BidaskClub downgraded shares of Cardiovascular Systems from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Citigroup Inc. initiated coverage on shares of Cardiovascular Systems in a research report on Thursday, September 21st. They set a “market perform” rating on the stock. Raymond James Financial, Inc. initiated coverage on shares of Cardiovascular Systems in a research report on Friday, September 22nd. They set a “market perform” rating on the stock. Needham & Company LLC reissued a “buy” rating and set a $37.00 price objective on shares of Cardiovascular Systems in a research report on Thursday, October 12th. Finally, Zacks Investment Research downgraded shares of Cardiovascular Systems from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $34.25.

About Cardiovascular Systems

Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.

Institutional Ownership by Quarter for Cardiovascular Systems (NASDAQ:CSII)

Receive News & Stock Ratings for Cardiovascular Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems Inc. and related stocks with our FREE daily email newsletter.